Zacks Investment Research upgraded Intellia Therapeutics Inc (NASDAQ:NTLA) to Hold in a report released today.
- Updated: October 8, 2016
Zacks Investment Research has upgraded Intellia Therapeutics Inc (NASDAQ:NTLA) to Hold in a report released on Thursday October 06, 2016.
Previously on Wednesday September 28, 2016, Janney Montgomery Scott reported on Intellia Therapeutics Inc (NASDAQ:NTLA) raised the target price from $0.00 to $29.00. At the time, this indicated a possible upside of 0.71%.
Yesterday Intellia Therapeutics Inc (NASDAQ:NTLA) traded -8.71% lower at $17.34. The company’s 50-day moving average is $19.25 and its 200-day moving average is $21.84. The last closing price is down -30.85% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 872,506 shares of the stock were exchanged, up from an average trading volume of 270,449
See Chart Below
Intellia Therapeutics Inc has a 52 week low of $14.88 and a 52 week high of $30.40 The company’s market cap is currently $0.
General Information About Intellia Therapeutics Inc (NASDAQ:NTLA)
Intellia Therapeutics, Inc. is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company's CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing. Its portfolio includes CRISPR/Cas9 platform technology, delivery technologies and nucleic acid modifications for human therapeutic use. The Company's CRISPR/Cas9 platform components include the guide ribonucleic acid (RNA) and the Cas9 nuclease (the genetic scissors). It has access to various delivery modalities specific to various in vivo and ex vivo approaches. The Company focuses on engineering ex vivo CRISPR/Cas9 cell therapies for chimeric antigen receptor T cell (CAR-T) and hematopoietic stem cell (HSC) applications. It also focuses on the use of in vivo Lipid Nanoparticle (LNP) delivery technology.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.